AJ Vaccines pauses to increase competitive strength

In order to increase its competitive strength on a strained market, AJ Vaccines is pausing parts of its produciton. The firm hopes to rearrange "a significant amount" of its around 40 employees, if positions are shut down.

Photo: Jan Bjarke Mindegaard / Watch Medier

The market situation, which is increasingly put under pressure, has caused AJ Vaccines to pause parts of its production of vaccines against tetanus, diphtheria and whooping cough (TdaP). This decisions will lead to 40 positions being shut down within the company.

AJ Vaccines CEO Jesper Helmuth Larsen says as much in an interview with MedWatch. More specifically, the production of the active ingredients in these three vaccines is halted for a period of time, whereas AJ Vaccines will try to make the production more cost-efficient.

Read this article for free

Register with your E-mail.
No credit card required.

Get full access for you and your coworkers.

Start a free company trial today

Related articles